Download PDF
Aktuelle Urol 2008; 39(6): 448-454
DOI: 10.1055/s-2008-1038282
Originalarbeit
© Georg Thieme Verlag KG Stuttgart · New York

Der Deutsche HTA-Report: Orchiektomie versus LH-RH-Analoga in der Therapie des fortgeschrittenen Prostatakarzinoms: Ergeben sich Konsequenzen für den Versorgungsalltag?

The German HTA Report: Orchiectomy versus LH-RH Analogues in the Treatment of Advanced Prostate Carcinoma: Are There Any Consequences For the Daily Health Service?V.  Rohde1, 3 , K.  Grabein3 , W.  Weidner1 , J.  Wasem2 , F.  Hessel2
  • 1Klinik und Poliklinik für Urologie und Kinderurologie, Universitätsklinikum Marburg und Gießen, Standort Gießen, Gießen
  • 2Lehrstuhl für Medizin-Management, Universität Duisburg-Essen, Essen
  • 3Helios Agnes Karll Krankenhaus Bad Schwartau, Bad Schwartau
Further Information

Publication History

Publication Date:
31 October 2008 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Fragestellung: In dieser systematischem Übersichtsarbeit wird die internationale Datenlage zur Effektivität der Hormondeprivation durch LH-RH-Analoga und der Orchiektomie zur Behandlung des fortgeschrittenen Prostatakarzinoms bewertet und im Kontext der primären, neoadjuvanten, adjuvanten und intermittierenden Hormondeprivation diskutiert. Material und Methoden: Zur Erschließung des Datenmaterials für dieses Health Technology Assessment wurde eine systematische, breit angelegte Literaturrecherche in den gängigen medizinischen und HTA-Datenbanken und weiteren Medien durchgeführt und die extrahierten Daten differenziert ausgewertet. Ergebnisse: In allen identifizierten, randomisierten, kontrollierten Studien zeigten RH-Analoga und Formen der Orchiektomie die gleiche medizinische Wirksamkeit. Hinsichtlich der Lebensqualität konnte in vier Studien unterschiedlichen Studiendesigns kein signifikanter Unterschied zwischen einer Behandlung mit LH-RH-Analoga und einer Therapie mit Orchiektomie gezeigt werden. Schlussfolgerung: Nach der gegenwärtig vorliegenden Studienlage gibt es klare Belege für die äquivalente Wirksamkeit von LH-RH-Analoga und einer Orchiektomie zur Therapie eines fortgeschrittenen Prostatakarzinoms. Eine Umkehr zur irreversiblen Orchiektomie, wenn auch gesundheitsökonomisch kostengünstiger, ist insbesondere unter der Berücksichtigung der erweiterten Indikationen zur temporären Hormondeprivation abschließend nicht empfehlenswert.

Abstract

Purpose: This systematic review evaluates international data on the medical effectiveness of orchiectomy and medical therapy with LH-RH analogues in patients with advanced prostate cancer. These results are discussed in the context of primary, neoadjuvant, adjuvant and intermittent hormone deprivation. Materials and Methods: A systematic, diversified literature analysis in the common medical and HTA databases and further media was conducted. Results: All identified, randomised and controlled studies concerning the application of LH-RH analogues showed the same medical effectiveness for orchiectomy and for treatment with LH-RH analogues. Four different studies regarding the quality of life revealed no significant difference between the treatment with LH-RH analogues and the therapy with orchiectomy. Conclusion: According to available studies, there is clear evidence for the equivalent effectiveness of LH-RH analogues and orchiectomy in the treatment of advanced prostate cancer. A change back to orchiectomy - even though it is more cost-efficient - cannot be recommended when taking the extended indications for temporary hormone deprivation into consideration.

Schlüsselwörter

Prostatakarzinom - Versorgungsalltag - Hormondeprivation - Effektivität

Key words

Prostate carcinoma - daily health service - hormondeprivation - effectiveness

Literatur

  • 1 Antes G BD, Forster J. Evidenz-basierte Medizin. Praxishandbuch für Verständnis und Anwendung der EBM. Stuttgart: Georg Thieme Verlag 2003
    Google Scholar
  • 2 Aronson N, Seidenfeld J, Samson D. et al .Relative effectiveness and cost-effectiveness of methods of androgen suppression in the treatment of advanced prostatic cancer. In: USA, Agency for Healthcare Research and Quality (AHRQ) 1998
    Google Scholar
  • 3 Aus G, Abbou C C, Bolla M. et al . EAU guidelines on prostate cancer.  European Urology. 2005;  48 546-551
    Google Scholar
  • 4 Banta D, Luce B R. Health Technology and its assessment. Oxford: Oxford University Press 1993
    Google Scholar
  • 5 Basaria S, Lieb J, Tang A M. et al . Long-term effects of androgen deprivation therapy in prostate cancer patients.  Clin Endocrinol (Oxf). 2002;  56 779-786
    Google Scholar
  • 6 Braga-Basaria M, Dobs A S, Muller D C. et al . Metabolic syndrome in men with prostate cancer undergoing long-term androgen-deprivation therapy.  J Clin Oncol. 2006;  24 3979-3983
    Google Scholar
  • 7 Care GSWGTAfH .„Toolkit” Informationsmaterial für Verfasser von HTA-Berichten. Hannover 2000
    Google Scholar
  • 8 Cassileth B R, Soloway M S, Vogelzang N J. et al . Patients" choice of treatment in stage D prostate cancer.  Urology. 1989;  33 57-62
    Google Scholar
  • 9 Cassileth B R, Soloway M S, Vogelzang N J. et al . Quality of life and psychosocial status in stage D prostate cancer.  Quality of Life Research. 1992;  1 323-330
    Google Scholar
  • 10 Chamberlain J, Melia J, Moss S. et al . Report prepared for the health technology assessment panel of the NHS executive on the diagnosis, management, treatment and costs of prostate cancer in England and Wales.  British Journal of Urology, Supplement. 1997;  79 1-32
    Google Scholar
  • 11 Conti P D, Atallah A N, Arruda H. et al . Intermittent versus continuous androgen suppression for prostatic cancer.  Cochrane Database Syst Rev. 2007;  CD005009
    Google Scholar
  • 12 Efficace F, Bottomley A, Van A. Health related quality of life in prostate carcinoma patients: A systematic review of randomized controlled trials.  CANCER. 2003;  97 377-388
    Google Scholar
  • 13 Efstathiou J A, Bae K, Shipley W U. et al . Cardiovascular Mortality and Duration of Androgen Deprivation for Locally Advanced Prostate Cancer: Analysis of RTOG 92 – 02.  Eur Urol. 2008;  54(4) 816-824
    Google Scholar
  • 14 Gerhardus A. The role of HTA in German health care. Do we need impact objectives?.  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2006;  49 233-240
    Google Scholar
  • 15 Heidenreich A AG, Abbou C G, Bolla M. et al .Guidelines on Prostate Cancer. European Association of Urology, Update March 2007. In: Recent Results Cancer Res 2007
    Google Scholar
  • 16 Huben R P, Murphy G P. A comparison of diethylstilbestrol or orchiectomy with buserelin and with methotrexate plus diethylstilbestrol or orchiectomy in newly diagnosed patients with clinical stage D2 cancer of the prostate.  CANCER. 1988;  62 1881-1887
    Google Scholar
  • 17 Kaisary A V, Tyrrell C J, Peeling W B. et al . Comparison of LHRH analogue (Zoladex) with orchiectomy in patients with metastatis prostatic carcinoma.  British Journal of Urology. 1991;  67 502-508
    Google Scholar
  • 18 Kaisary A V, Ryan P G, Turkes A. et al . A comparison between surgical orchidectomy and LH-RH analogue ('Zoladex', ICI 118,630) in the treatment of advanced prostatic carcinoma – a multi-centre clinical study.  Prog Clin Biol Res. 1988;  260 89-100
    Google Scholar
  • 19 Kawakami J, Cowan J E, Elkin E P. et al . Androgen-deprivation therapy as primary treatment for localized prostate cancer: data from Cancer of the Prostate Strategic Urologic Research Endeavor (CaPSURE).  Cancer. 2006;  106 1708-1714
    Google Scholar
  • 20 Keating N L, O'Malley A J, Smith M R. Diabetes and cardiovascular disease during androgen deprivation therapy for prostate cancer.  J Clin Oncol. 2006;  24 4448-4456
    Google Scholar
  • 21 Klioze S S, Miller M F, Spiro T P. A randomized, comparative study of buserelin with DES/orchiectomy in the treatment of stage D2 prostatic cancer patients.  American Journal of Clinical Oncology. 1988;  11 Suppl 2 S176-S182
    Google Scholar
  • 22 Koutsilieris M, Tolis G. Long-term follow-up of patients with advanced prostatic carcinoma treated with either buserelin (HOE 766) or orchiectomy: classification of variables associated with disease outcome.  Prostate. 1985;  7 31-39
    Google Scholar
  • 23 Kulp W, Greiner W. Health economics and HTA.  Bundesgesundheitsblatt Gesundheitsforschung Gesundheitsschutz. 2006;  49 257-263
    Google Scholar
  • 24 Kumar S, Shelley M, Harrison C. et al . Neo-adjuvant and adjuvant hormone therapy for localised and locally advanced prostate cancer.  Cochrane Database Syst Rev. 2006;  CD006019
    Google Scholar
  • 25 Litwin M S, Penson D F. Health-related quality of life in men with prostate cancer.  Prostate Cancer Prostatic Dis. 1998;  1 228-235
    Google Scholar
  • 26 Miyamoto H, Messing E, Chang C. Androgen deprivation therapy for prostate cancer: current status and future prospects.  Prostate. 2004;  61 332-353
    Google Scholar
  • 27 Nygård R, Norum J, Due J. Goserelin (Zoladex) or orchiectomy in metastatic prostate cancer? A quality of life and cost-effectiveness analysis.  Anticancer Research. 2001;  21 781-788
    Google Scholar
  • 28 Oliver A, Mossialos E, Robinson R. Health technology assessment and its influence on health-care priority setting.  Int J Technol Assess Health Care. 2004;  20 1-10
    Google Scholar
  • 29 Peeling W B. Phase III studies to compare goserelin (Zoladex) with orchiectomy and with diethylstilbestrol in treatment of prostatic carcinoma.  Urology. 1989;  33 45-52
    Google Scholar
  • 30 Potosky A L, Reeve B B, Clegg L X. et al . Quality of life following localized prostate cancer treated initially with androgen deprivation therapy or no therapy.  J Natl Cancer Inst. 2002;  94 430-437
    Google Scholar
  • 31 Rohde V, Wellmann A, Fogt F. et al . Economical data and advanced prostate carcinoma: do we need new guidelines for decision making?.  Oncology reports. 2002;  9 1185-1188
    Google Scholar
  • 32 Rohde V, Hessel F, Grabein K. et al . Orchiektomie versus medikamentöse Therapie mit LH-RH-Analoga zur Behandlung des fortgeschrittenen Prostatakarzinoms.  GMS Health Technol Asssess. 2006;  2 Doc13-D0013
    Google Scholar
  • 33 Rohde V, Diemer T, Hauck E. et al . Prescription practice for LH-RH analogs and androgen receptor antagonists in the treatment of advanced prostate cancer in Germany (1993 – 2003).  Urol Int. 2006;  77 311-316
    Google Scholar
  • 34 Rohde V, Diemer T, Hauck E. et al . Prescription practice for LH-RH analogs and androgen receptor antagonists in the treatment of advanced prostate cancer in Germany (1993 – 2003).  Urologia internationalis. 2006;  77 311-316
    Google Scholar
  • 35 Ryan P G, Peeling W B. U.K. trials of treatment for M1 prostatic cancer. The LH-RH analogue Zoladex vs. orchidectomy.  American Journal of Clinical Oncology. 1988;  11 Suppl 2 S169-S172
    Google Scholar
  • 36 Sawicki P. Nutzenbewertung in der Medizin - Stand Oktober 2006.  Gesundh Ökon Qual Manag. 2006;  11 356-367
    Google Scholar
  • 37 Seidenfeld J, Samson D J, Hasselblad V. et al . Single-therapy androgen suppression in men with advanced prostate cancer: a systematic review and meta-analysis.  Annals of internal medicine. 2000;  132 566-577
    Google Scholar
  • 38 Shahani S, Braga-Basaria M, Basaria S. Androgen deprivation therapy in prostate cancer and metabolic risk for atherosclerosis.  J Clin Endocrinol Metab. 2008;  93 2042-2049
    Google Scholar
  • 39 Shahinian V B, Kuo Y F, Freeman J L. et al . Risk of fracture after androgen deprivation for prostate cancer.  N Engl J Med. 2005;  352 154-164
    Google Scholar
  • 40 Solomon C B, Solomon C, Best L. Goserelin or other gonadotrophin releasing hormone (GnRH) analogues in the treatment of advanced prostate cancer. In. Great Britain: Wessex Institute for Health Research and Development 1996
    Google Scholar
  • 41 Soloway M S, Chodak G, Vogelzang N J. et al . Zoladex versus orchiectomy in treatment of advanced prostate cancer: A randomized trial.  Urology. 1991;  37 46-51
    Google Scholar
  • 42 Spry N A, Kristjanson L, Hooton B. et al . Adverse effects to quality of life arising from treatment can recover with intermittent androgen suppression in men with prostate cancer.  Eur J Cancer. 2006;  42 1083-1092
    Google Scholar
  • 43 Staquet M, Berzon R, Osoba D. et al . Guidelines for reporting results of quality of life assessments in clinical trials.  Qual Life Res. 1998;  5 496-502
    Google Scholar
  • 44 Turkes A O, Peeling W B, Griffiths K. Treatment of patients with advanced cancer of the prostate: phase III trial, zoladex against castration; a study of the British Prostate Group.  J Steroid Biochem. 1987;  27 543-549
    Google Scholar
  • 45 Vogelzang N J, Chodak G W, Soloway M S. et al . Goserelin versus orchiectomy in the treatment of advanced prostate cancer: Final results of a randomized trial.  Urology. 1995;  46 220-226
    Google Scholar
  • 46 Wright J, Higano , CS , Lin D W. Intermittent androgen deprivation: clinical experience and practical applications.  Urol Clin North Am. 2006;  33(2) 167-179
    Google Scholar

Dr. med. Volker Rohde

Klinik und Poliklinik für Urologie und Kinderurologie, Universitätsklinikum Marburg und Gießen, Standort Gießen

Rudolf Buchheim Str. 7

35385 Gießen

Phone: 06841/9944505

Email: vrohde@gmx.de

      >